Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more
Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) - Net Assets
Latest net assets as of September 2025: CN¥1.15 Billion CNY
Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has net assets worth CN¥1.15 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.01 Billion) and total liabilities (CN¥1.86 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.15 Billion |
| % of Total Assets | 38.13% |
| Annual Growth Rate | 35.62% |
| 5-Year Change | -25.95% |
| 10-Year Change | N/A |
| Growth Volatility | 724.42 |
Suzhou Zelgen Biopharmaceuticals Co Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual net assets of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.25 Billion | -23.85% |
| 2023-12-31 | CN¥1.64 Billion | +108.87% |
| 2022-12-31 | CN¥787.49 Million | -37.16% |
| 2021-12-31 | CN¥1.25 Billion | -25.92% |
| 2020-12-31 | CN¥1.69 Billion | +2193.68% |
| 2019-12-31 | CN¥73.75 Million | -73.81% |
| 2018-12-31 | CN¥281.64 Million | +285.68% |
| 2017-12-31 | CN¥73.02 Million | -33.27% |
| 2016-12-31 | CN¥109.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Suzhou Zelgen Biopharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 190656621173.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥264.71 Million | 21.11% |
| Other Comprehensive Income | CN¥60.79 Million | 4.85% |
| Other Components | CN¥3.05 Billion | 242.86% |
| Total Equity | CN¥1.25 Billion | 100.00% |
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Diamondrock Hospitality Company Common Stock
NYSE:DRH
|
$1.89 Billion |
|
Exchange Income Corporation
PINK:EIFZF
|
$1.89 Billion |
|
Zhejiang Jinke Peroxides Co Ltd
SHE:300459
|
$1.89 Billion |
|
Vietjet Aviation JSC
VN:VJC
|
$1.89 Billion |
|
Christian Dior SE
PINK:CHDRF
|
$1.89 Billion |
|
Guangdong Jia Yuan Technology Co Ltd
SHG:688388
|
$1.89 Billion |
|
Swatch Group AG Class N
SW:UHRN
|
$1.89 Billion |
|
CENTESSA PHARMACEUTICALS
F:260
|
$1.89 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Suzhou Zelgen Biopharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,632,852,717 to 1,253,857,931, a change of -378,994,786 (-23.2%).
- Net loss of 137,830,774 reduced equity.
- Dividend payments of 24,563,574 reduced retained earnings.
- Other comprehensive income decreased equity by 7,266,777.
- Other factors decreased equity by 209,333,661.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-137.83 Million | -10.99% |
| Dividends Paid | CN¥24.56 Million | -1.96% |
| Other Comprehensive Income | CN¥-7.27 Million | -0.58% |
| Other Changes | CN¥-209.33 Million | -16.7% |
| Total Change | CN¥- | -23.21% |
Book Value vs Market Value Analysis
This analysis compares Suzhou Zelgen Biopharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.69x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 129.65x to 16.69x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | CN¥0.61 | CN¥78.95 | x |
| 2017-12-31 | CN¥0.41 | CN¥78.95 | x |
| 2018-12-31 | CN¥1.26 | CN¥78.95 | x |
| 2019-12-31 | CN¥0.01 | CN¥78.95 | x |
| 2020-12-31 | CN¥6.74 | CN¥78.95 | x |
| 2021-12-31 | CN¥4.98 | CN¥78.95 | x |
| 2022-12-31 | CN¥3.16 | CN¥78.95 | x |
| 2023-12-31 | CN¥6.39 | CN¥78.95 | x |
| 2024-12-31 | CN¥4.73 | CN¥78.95 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Suzhou Zelgen Biopharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -25.86%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 2.40x
- Recent ROE (-10.99%) is above the historical average (-1570.99%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -117.21% | -64027.01% | 0.00x | 1.25x | CN¥-139.21 Million |
| 2017 | -200.57% | 0.00% | 0.00x | 2.02x | CN¥-153.77 Million |
| 2018 | -194.46% | -33564.91% | 0.00x | 2.01x | CN¥-462.72 Million |
| 2019 | -13480.92% | 0.00% | 0.00x | 93.48x | CN¥-462.22 Million |
| 2020 | -19.73% | -1154.08% | 0.01x | 1.22x | CN¥-481.00 Million |
| 2021 | -37.70% | -236.92% | 0.11x | 1.46x | CN¥-570.63 Million |
| 2022 | -60.24% | -151.28% | 0.18x | 2.20x | CN¥-533.24 Million |
| 2023 | -17.06% | -72.09% | 0.13x | 1.77x | CN¥-441.87 Million |
| 2024 | -10.99% | -25.86% | 0.18x | 2.40x | CN¥-263.22 Million |
Industry Comparison
This section compares Suzhou Zelgen Biopharmaceuticals Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) | CN¥1.15 Billion | -117.21% | 1.62x | $1.89 Billion |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |